To find out whether increased IL-6 and TGF-β1 plasma levels after completion of RT originate from the tumour, IL-6 and TGF-β1 plasma concentrations measured at defined time-points during follow-up were plotted against the concurrently determined tumour responses of every patient (fig. The gene discussed is TGFB1; the disease is neoplasm.